🇧🇷Brazil

Risco de Desvio e Furto de Medicamentos Controlados por Falta de Rastreabilidade em Tempo Real

3 verified sources

Definition

Portaria 344/1998 mandates inventory control via SNGPC. Controlled substances include psychotropic drugs, opioids, antiretrovirals, and anabolics—high-value, high-theft targets. Manual batch reporting (e.g., daily or weekly) delays detection of discrepancies. No real-time variance alerts = opportunity for employee theft, customer fraud (false prescriptions), or accounting errors to accumulate.

Key Findings

  • Financial Impact: LOGIC-based estimate: Average shrinkage rate 1–3% of controlled-substance inventory. For a mid-sized pharmacy (R$ 100,000/month in controlled-substance revenue): R$ 1,000–R$ 3,000/month loss. For pharmacy network (50 locations): R$ 50,000–R$ 150,000/month undetected shrinkage. Annual impact: R$ 600,000–R$ 1.8M per network.
  • Frequency: Ongoing; detected only during monthly or quarterly physical inventory counts (creating audit lag).
  • Root Cause: Manual SNGPC entry; lack of real-time POS-SNGPC synchronization; delayed variance reporting; insufficient role-based access controls in SNGPC (multiple staff can adjust inventory); no automated alerts for out-of-range discrepancies.

Why This Matters

The Pitch: Brazilian pharmacies lose 1–3% of controlled-substance inventory annually to shrinkage (theft/diversion). Real-time SNGPC-POS integration with automated reconciliation detects variance within minutes, reducing shrinkage by 30–50% and eliminating monthly inventory write-offs of R$ 5,000–R$ 20,000 per location.

Affected Stakeholders

Warehouse/Stock Manager, Pharmacy Technician (access to controlled inventory), Pharmacist (responsible for accountability), Internal Audit / Compliance

Deep Analysis (Premium)

Financial Impact

Financial data and detailed analysis available with full access. Unlock to see exact figures, evidence sources, and actionable insights.

Unlock to reveal

Current Workarounds

Financial data and detailed analysis available with full access. Unlock to see exact figures, evidence sources, and actionable insights.

Unlock to reveal

Get Solutions for This Problem

Full report with actionable solutions

$99$39
  • Solutions for this specific pain
  • Solutions for all 15 industry pains
  • Where to find first clients
  • Pricing & launch costs
Get Solutions Report

Methodology & Sources

Data collected via OSINT from regulatory filings, industry audits, and verified case studies.

Evidence Sources:

Related Business Risks

Penalidades por Não-Conformidade ao SNGPC (Portaria 344/1998)

LOGIC-based estimate: Typical ANVISA administrative fines for non-compliance range R$ 5,000–R$ 50,000 per violation; larger networks face R$ 100,000+ for systemic SNGPC failures. Operational costs from license suspensions or revocation: loss of controlled-substance revenue (15–30% of pharmacy revenue), estimated R$ 50,000–R$ 500,000+ per pharmacy per month during suspension.

Atraso Operacional por Registro Manual no SNGPC (Sistema Nacional de Gerenciamento de Produtos Controlados)

LOGIC-based estimate: 2–5 minutes per controlled-substance transaction × 20–50 controlled transactions/day per pharmacy × 22 working days/month = 14.6–110 hours/month of technician time (R$ 880–R$ 6,600/month at R$ 60/hour blended cost). For pharmacy networks with 50+ locations: R$ 44,000–R$ 330,000/month in lost labor capacity.

Erros de Decisão por Falta de Visibilidade em Tempo Real sobre Estoque de Medicamentos Controlados

LOGIC-based estimate: 2–5% inventory waste (expiration/spoilage) on R$ 100,000/month controlled-substance revenue = R$ 2,000–R$ 5,000/month. 5–10% stock-out-driven lost sales = R$ 5,000–R$ 10,000/month forgone margin. Combined: R$ 7,000–R$ 15,000/month per pharmacy. Network (50 locations): R$ 350,000–R$ 750,000/month. Annual: R$ 4.2M–R$ 9M.

Multa por Violação de LGPD e Privacidade do Consumidor

R$ 8,497,500.00 (confirmed fine); potential industry exposure: R$ 50,000–R$ 3,000,000 per administrative proceeding depending on scale and intent.

Risco de Recusa de Cobertura de Plano de Saúde por Violação de Dados Sensíveis

Per-customer litigation cost: R$ 10,000–R$ 50,000; churn impact: 2–5% customer base loss annually; class action risk: R$ 5,000,000+.

Perda por Vencimento de Medicamentos (Product Expiration Waste)

Estimated: R$ 2,000–25,000 annually per pharmacy (2–5% of typical inventory value of R$ 100,000–500,000). Pharmacy chains with 10+ locations: R$ 20,000–250,000+ annually.

Request Deep Analysis

🇧🇷 Be first to access this market's intelligence